Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Human B cell malignancies exhibit resistance to apoptosis, a key factor in treatment failure.
• Current therapies include small-molecule inhibitors of anti-apoptotic proteins and B-cell receptor (BCR) signaling, as well as antibody-based therapies targeting tumor-associated antigens (TAAs).

Purpose of the Study:

• To review current management strategies for B cell malignancies.
• To highlight novel therapeutic approaches and ongoing clinical development for B cell cancers.
• To explore the potential of targeting metabolic reprogramming in B cell disorders.

Main Methods:

• Review of current literature on B cell malignancy treatments.
• Analysis of small-molecule inhibitors and antibody-based therapies.
• Discussion of emerging strategies including TAA-targeting agents and metabolic checkpoint inhibitors.

Main Results:

• Small-molecule inhibitors (e.g., Bcl-2, Bruton's tyrosine kinase, phosphatidylinositol-3 kinase) and antibody-based therapies (e.g., targeting CD19, CD20, CD22, CD38) are established treatments.
• Despite progress, patient refractory disease and relapse necessitate novel therapeutic strategies.
• Metabolic reprogramming significantly impacts B cell pathophysiology, suggesting potential therapeutic targets.

Conclusions:

• Ongoing development focuses on more effective and selective drugs targeting key molecules and TAAs in B cell malignancies.
• Targeting metabolic checkpoints presents a promising avenue for treating these disorders.
• Innovative therapeutic strategies are crucial to overcome resistance and improve outcomes in B cell cancers.